Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Ivabradine Ameliorates Kidney Fibrosis in L-NAME-Induced Hypertension

P. Stanko, T. Baka, K. Repova, S. Aziriova, K. Krajcirovicova, A. Barta, P. Janega, M. Adamcova, L. Paulis, F. Simko,

. 2020 ; 7 (-) : 325. [pub] 20200710

Language English Country Switzerland

Document type Journal Article

Hypertension-induced renal injury is characterized by structural kidney alterations and function deterioration. Therapeutics for kidney protection are limited, thus novel renoprotectives in hypertension are being continuously sought out. Ivabradine, an inhibitor of the If current in the sinoatrial node reducing heart rate (HR), was shown to be of benefit in various cardiovascular pathologies. Yet, data regarding potential renoprotection by ivabradine in hypertension are sparse. Thirty-six adult male Wistar rats were divided into non-diseased controls and rats with NG-nitro-L-arginine methyl ester (L-NAME)-induced hypertension to assess ivabradine's site-specific effect on kidney fibrosis. After 4 weeks of treatment, L-NAME increased the average systolic blood pressure (SBP) (by 27%), decreased glomerular density (by 28%) and increased glomerular tuft area (by 44%). Moreover, L-NAME induced glomerular, tubulointerstitial, and vascular/perivascular fibrosis by enhancing type I collagen volume (16-, 19- and 25-fold, respectively). L-NAME also increased the glomerular type IV collagen volume and the tubular injury score (3- and 8-fold, respectively). Ivabradine decreased average SBP and HR (by 8 and 12%, respectively), increased glomerular density (by 57%) and reduced glomerular tuft area (by 30%). Importantly, ivabradine decreased type I collagen volume at all three of the investigated sites (by 33, 38, and 72%, respectively) and enhanced vascular/perivascular type III collagen volume (by 67%). Furthermore, ivabradine decreased the glomerular type IV collagen volume and the tubular injury score (by 63 and 34%, respectively). We conclude that ivabradine attenuated the alterations of glomerular density and tuft area and modified renal fibrosis in a site-specific manner in L-NAME-hypertension. It is suggested that ivabradine may be renoprotective in hypertensive kidney disease.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20021988
003      
CZ-PrNML
005      
20201204093515.0
007      
ta
008      
201125s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fmed.2020.00325 $2 doi
035    __
$a (PubMed)32754607
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Stanko, Peter $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
245    10
$a Ivabradine Ameliorates Kidney Fibrosis in L-NAME-Induced Hypertension / $c P. Stanko, T. Baka, K. Repova, S. Aziriova, K. Krajcirovicova, A. Barta, P. Janega, M. Adamcova, L. Paulis, F. Simko,
520    9_
$a Hypertension-induced renal injury is characterized by structural kidney alterations and function deterioration. Therapeutics for kidney protection are limited, thus novel renoprotectives in hypertension are being continuously sought out. Ivabradine, an inhibitor of the If current in the sinoatrial node reducing heart rate (HR), was shown to be of benefit in various cardiovascular pathologies. Yet, data regarding potential renoprotection by ivabradine in hypertension are sparse. Thirty-six adult male Wistar rats were divided into non-diseased controls and rats with NG-nitro-L-arginine methyl ester (L-NAME)-induced hypertension to assess ivabradine's site-specific effect on kidney fibrosis. After 4 weeks of treatment, L-NAME increased the average systolic blood pressure (SBP) (by 27%), decreased glomerular density (by 28%) and increased glomerular tuft area (by 44%). Moreover, L-NAME induced glomerular, tubulointerstitial, and vascular/perivascular fibrosis by enhancing type I collagen volume (16-, 19- and 25-fold, respectively). L-NAME also increased the glomerular type IV collagen volume and the tubular injury score (3- and 8-fold, respectively). Ivabradine decreased average SBP and HR (by 8 and 12%, respectively), increased glomerular density (by 57%) and reduced glomerular tuft area (by 30%). Importantly, ivabradine decreased type I collagen volume at all three of the investigated sites (by 33, 38, and 72%, respectively) and enhanced vascular/perivascular type III collagen volume (by 67%). Furthermore, ivabradine decreased the glomerular type IV collagen volume and the tubular injury score (by 63 and 34%, respectively). We conclude that ivabradine attenuated the alterations of glomerular density and tuft area and modified renal fibrosis in a site-specific manner in L-NAME-hypertension. It is suggested that ivabradine may be renoprotective in hypertensive kidney disease.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Baka, Tomas $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
700    1_
$a Repova, Kristina $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
700    1_
$a Aziriova, Silvia $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
700    1_
$a Krajcirovicova, Kristina $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
700    1_
$a Barta, Andrej $u Institute of Normal and Pathological Physiology, Centre of Experimental Medicine, Slovak Academy of Sciences, Bratislava, Slovakia.
700    1_
$a Janega, Pavol $u Institute of Normal and Pathological Physiology, Centre of Experimental Medicine, Slovak Academy of Sciences, Bratislava, Slovakia. Institute of Pathological Anatomy, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
700    1_
$a Adamcova, Michaela $u Department of Physiology, School of Medicine, Charles University, Prague, Czechia.
700    1_
$a Paulis, Ludovit $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia. Institute of Normal and Pathological Physiology, Centre of Experimental Medicine, Slovak Academy of Sciences, Bratislava, Slovakia.
700    1_
$a Simko, Fedor $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia. 3rd Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia. Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia.
773    0_
$w MED00188756 $t Frontiers in medicine $x 2296-858X $g Roč. 7, č. - (2020), s. 325
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32754607 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201204093512 $b ABA008
999    __
$a ind $b bmc $g 1591696 $s 1112660
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 7 $c - $d 325 $e 20200710 $i 2296-858X $m Frontiers in medicine $n Front. med. $x MED00188756
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...